Capacity Bio, Inc.

PALO ALTO, CA · Founded 2021 · Biotech · Private

Mitophagy therapeutic platform and mitochondrial characterization analytical toolkit

Claim this profile

Follows are private to you and power your alerts

Updated · capacitybio.com

Sector
Biotech
Headquarters
PALO ALTO, CA
Founded
2021
Latest Form D
$19.2M, Jan 2023
Total capital
$19.2M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$19.2M
1 Form D · last Jan 2023
45 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
3 pending · first 2025
Rank in peer group#481 of 1449

Capital timeline

2023FEDERAL ↑EQUITY ↓Cumulative $19.2M1st Form D$19.2M
2023FEDERAL ↑EQUITY ↓Cumulative $19.2M1st Form D$19.2M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$19.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Amy WangResearcherExecutive Officer, DirectorLinked by 1 patent
  • Cristina GhenoiuDirectorNamed in SEC Form D filings
  • Dylan MorrisDirectorNamed in SEC Form D filings
  • Kenneth HorneExecutive Officer, DirectorNamed in SEC Form D filings
  • Taro InabaDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 4
Show all 4 patent records
  • Methods And Agents That Stimulate Mitochondrial Turnover For Treating DiseaseMar 5, 2026 · Application 19212461Pending
  • Methods And Agents That Stimulate Mitochondrial Turnover For Treating DiseaseJul 1, 2025 · US 12,343,331Granted
  • Methods And Agents That Stimulate Mitochondrial Turnover For Treating DiseaseApplication PCTUS2022014330Pending
  • Methods And Agents That Stimulate Mitochondrial Turnover For Treating DiseaseApplication 63142683Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .